Holen Sie sich die Stockscreener-App
1.025
5.96%
-0.065
Schlusskurs vom Vortag:
$1.09
Offen:
$1.09
24-Stunden-Volumen:
1.54M
Relative Volume:
4.34
Marktkapitalisierung:
$94.18M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.15M
KGV:
-1.1264
EPS:
-0.91
Netto-Cashflow:
$-31.63M
1W Leistung:
-9.29%
1M Leistung:
-7.66%
6M Leistung:
+78.17%
1J Leistung:
-32.12%
1-Tages-Spanne:
$1.00
$1.10
1-Wochen-Bereich:
$1.00
$1.18
52-Wochen-Spanne:
$0.49
$1.61
Context Therapeutics Inc Stock (CNTX) Company Profile
Firmenname
Context Therapeutics Inc
Sektor
Branche
Telefon
267-225-7416
Adresse
2001 MARKET STREET, PHILADELPHIA
Vergleichen Sie CNTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
1.025 | 100.15M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | Guggenheim | Buy |
| 2025-04-21 | Eingeleitet | William Blair | Outperform |
| 2025-01-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-11-25 | Eingeleitet | D. Boral Capital | Buy |
| 2024-05-16 | Eingeleitet | Piper Sandler | Overweight |
Context Therapeutics Inc Aktie (CNTX) Neueste Nachrichten
Is Context Therapeutics Inc. stock attractive for growth ETFs2025 Volume Leaders & AI Powered Trade Plan Recommendations - Newser
Why Context Therapeutics Inc. stock remains on buy listsMarket Growth Report & Momentum Based Trading Signals - BỘ NỘI VỤ
CT-202, a tumor-selective pH-dependent Nectin-4/CD3 TCE - BioWorld MedTech
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.40 Average Target Price from Brokerages - Defense World
Context Therapeutics (NASDAQ:CNTX) Upgraded to “Sell” at Wall Street Zen - Defense World
What drives Context Therapeutics Inc stock priceTrading Volume Trends & Affordable Growth Strategies - earlytimes.in
What technical charts say about Context Therapeutics Inc. stockWeekly Stock Analysis & Free Fast Gain Swing Trade Alerts - newser.com
Why analysts remain bullish on Context Therapeutics Inc. stockSwing Trade & Accurate Intraday Trading Signals - newser.com
Is Context Therapeutics Inc. stock a safe buy before earnings2025 Performance Recap & Technical Entry and Exit Alerts - newser.com
Is Context Therapeutics Inc. stock poised for growthJuly 2025 Decliners & Long-Term Growth Plans - newser.com
Century Therapeutics Debuts Immune-Evasive Cell Therapy Aiming to Transform Type 1 Diabetes - MyChesCo
Passage Bio Pushes Toward Key 2026 Milestones as Gene Therapy Program Accelerates - MyChesCo
Using portfolio simulators with Context Therapeutics Inc. includedMarket Growth Report & Long-Term Capital Growth Ideas - newser.com
Published on: 2025-11-16 17:23:15 - newser.com
What’s the recovery path for long term holders of Context Therapeutics Inc.Market Risk Report & Daily Stock Momentum Reports - newser.com
Is Context Therapeutics Inc. stock resilient to inflationJuly 2025 Snapshot & Fast Moving Stock Watchlists - newser.com
Published on: 2025-11-15 13:42:26 - newser.com
Exit strategy if you’re trapped in Context Therapeutics Inc.July 2025 WrapUp & AI Enhanced Trading Alerts - newser.com
Is Context Therapeutics Inc. stock a top pick in earnings seasonJuly 2025 Trade Ideas & Smart Money Movement Alerts - newser.com
Is Context Therapeutics Inc. stock positioned well for digital economyGlobal Markets & Risk Controlled Daily Plans - newser.com
How institutional buying supports Context Therapeutics Inc. stockAnalyst Downgrade & Stepwise Trade Signal Guides - Fundação Cultural do Pará
Does Context Therapeutics Inc. stock trade at a discount to peers2025 Dividend Review & Verified Entry Point Detection - newser.com
Aclaris Therapeutics Advances Immuno-Inflammatory Pipeline, Targets Four Clinical Programs in 2026 - MyChesCo
Context Therapeutics Reports Encouraging Early Data in Cancer Trials, Eyes 2026 Milestones - MyChesCo
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting - Black Hills Pioneer
Is Context Therapeutics Inc. stock a defensive play in 2025July 2025 Reactions & Daily Profit Focused Screening - newser.com
Private equity firms who hold 46% of Context Therapeutics Inc. (NASDAQ:CNTX) gained 11%, institutions profited as well - simplywall.st
Finanzdaten der Context Therapeutics Inc-Aktie (CNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Context Therapeutics Inc-Aktie (CNTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Levit Alex C. | Chief Legal Officer, Corp. Sec |
Jun 06 '25 |
Buy |
0.58 |
20,000 |
11,520 |
29,000 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer |
Jun 06 '25 |
Buy |
0.64 |
40,010 |
25,486 |
80,010 |
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):